Abstract Background Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated. Methods The cohort of PD patients attending our center which tackled the challenge of a restricted use of hypertonic glucose solutions has been prospectively followed since 1992. Small-solute transport was assessed using an equivalent of the glucose peritoneal equilibration test after 6 months, and then every year. Study was stopped on July 1st, 2008, before use of biocompatible solutions. Repeated measures in patients treated with PD for 54 months were analyzed by using (1) the slopes of the linear r...
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (bio...
Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Bac...
BACKGROUND: In end-stage renal disease patients treated with peritoneal dialysis (PD), the osmotic c...
International audienceBACKGROUND:Glucose is widely used as an osmotic agent in peritoneal dialysis (...
Background: Glucose is the most commonly used osmotic medium in peritoneal dialysis (PD) solutions, ...
Long-term exposure to a high glucose concentration in conventional peritoneal dialysis (PD) solution...
♦ The quality of the peritoneal membrane can deteriorate over time. Exposure to glucose-based dialys...
BACKGROUND: Glucose degradation products (GDPs) are cytotoxic in vitro and potentially toxic in vivo...
Glucose-based peritoneal dialysis (PD) solutions are the mainstay of therapy for PD patients, yet ar...
For patients on peritoneal dialysis (PD), the development of peritonitis, the decline of residual ki...
INTRODUCTION AND AIMS: Peritoneal dialysis (PD) solutions using glucose as osmotic agent have been u...
Clinical experience and literature evidence suggest that peritoneal dialysis (PD) is a safe and effe...
Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients trea...
INTRODUCTION: Loss of residual renal function (RRF) as well as high peritoneal glucose exposure are ...
Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients trea...
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (bio...
Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Bac...
BACKGROUND: In end-stage renal disease patients treated with peritoneal dialysis (PD), the osmotic c...
International audienceBACKGROUND:Glucose is widely used as an osmotic agent in peritoneal dialysis (...
Background: Glucose is the most commonly used osmotic medium in peritoneal dialysis (PD) solutions, ...
Long-term exposure to a high glucose concentration in conventional peritoneal dialysis (PD) solution...
♦ The quality of the peritoneal membrane can deteriorate over time. Exposure to glucose-based dialys...
BACKGROUND: Glucose degradation products (GDPs) are cytotoxic in vitro and potentially toxic in vivo...
Glucose-based peritoneal dialysis (PD) solutions are the mainstay of therapy for PD patients, yet ar...
For patients on peritoneal dialysis (PD), the development of peritonitis, the decline of residual ki...
INTRODUCTION AND AIMS: Peritoneal dialysis (PD) solutions using glucose as osmotic agent have been u...
Clinical experience and literature evidence suggest that peritoneal dialysis (PD) is a safe and effe...
Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients trea...
INTRODUCTION: Loss of residual renal function (RRF) as well as high peritoneal glucose exposure are ...
Previous studies report conflicting results on the benefit of peritoneal dialysis (PD) patients trea...
BACKGROUND: The balANZ trial recently reported that neutral pH, low glucose degradation product (bio...
Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Bac...
BACKGROUND: In end-stage renal disease patients treated with peritoneal dialysis (PD), the osmotic c...